Nonalcoholic steatohepatitis: an expanded clinical entity.
about
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitisNonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and managementClinical and histological features of nonalcoholic steatohepatitis in Iranian patientsThe Natural Course of Non-Alcoholic Fatty Liver DiseaseInsulin resistance in development and progression of nonalcoholic fatty liver diseaseEndocrine causes of nonalcoholic fatty liver diseaseIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseTreatment of nonalcoholic steatohepatitis in adults: present and futureRole of mitochondria in nonalcoholic fatty liver diseasePathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiologyBiomarkers in nonalcoholic fatty liver diseaseMetabolic and cardiovascular complications in the liver transplant recipientTransitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease during the last three decadesThe global epidemiology of hepatocellular carcinoma: present and futureSources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?Association between nocturnal hypoxia and liver injury in the setting of nonalcoholic fatty liver disease.Diagnosis of alcoholic liver disease.Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis.Cirrhosis of liver.Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease.Dietary saponins of sea cucumber alleviate orotic acid-induced fatty liver in rats via PPARalpha and SREBP-1c signalingPreventive care in chronic liver disease.Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitisSerum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver diseaseAssociation of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.Fatty liver in H63D homozygotes with hyperferritinemiaPortal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research networkPioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.Non-alcoholic steatohepatitis and influence of age and gender on histopathologic findingsFibroblast growth factor-5 participates in the progression of hepatic fibrosis.Iron overload cardiomyopathy: better understanding of an increasing disorder.Liver biopsy in a district general hospital: changes over two decadesNonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations.Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.Gender-related variations in iron metabolism and liver diseases.MR quantification of total liver fat in patients with impaired glucose tolerance and healthy subjectsPrevalence of hepatopathy in type 1 diabetic children
P2860
Q24625697-FF2ADAB1-438A-482A-857C-B69379843C5CQ24649618-CB20EF7B-265B-438D-B0E9-64CAB7B23CA0Q24792885-FBB41F0B-47BA-434D-8095-157090789CBFQ26746947-32569665-E8EE-425E-AD79-0F62575D29B5Q26748687-A4B09B63-D4B2-468F-9B1B-4956857A01FEQ26780254-3478F55D-0CF9-479C-AE07-2CBBBB8D2973Q26827183-78786329-DC31-4B2E-9090-6FE737083B42Q26852403-98B08761-6785-44EA-8EDC-D2E004CA507EQ27028142-5B57028E-58AA-424A-A1FE-A599079CE0CBQ27477846-7DCA5C3C-248B-4640-B8D4-F23C9D53BF97Q28080541-B30C9224-8483-4C04-AF5F-F9A764165D88Q28082243-64F5C603-765D-4808-82E5-8A926890C71CQ28088798-8E58F159-A8FC-4495-9889-0B4108F66550Q28654353-8DC10758-86C7-40FC-B12C-604DE1299FC5Q29619334-F29AF1F2-645D-4098-B044-FF7C06C9E7B4Q30234736-C345B04C-4B73-4E87-8614-39160DD51123Q30418433-54039D2D-F11E-4346-9A5F-BBF9C734A364Q30431186-7C2063EB-CA45-4CBF-A296-CC809169F3C3Q30479092-EF1A28DA-742E-4FBA-83BC-00AEFB516749Q30479629-2B975DEF-9A6C-4B17-97A8-6B7E8A0D9A5DQ33321721-4A129409-DE49-4FF8-A25D-3D5FFECCD0B1Q33746278-9ED8B6A3-F27D-404B-97C9-34B30B2E692AQ33756919-AF8660B4-B77F-426D-A7A4-528A37B166FFQ33758991-6CBBD036-4726-498B-AFF0-10285231030AQ33778884-C7E43941-E69C-4F01-BE20-2D31A23A9D01Q33788174-2928B193-293C-4DCE-A301-7701DD2E45CEQ33990346-1D5AA244-22BC-4DF5-9D47-D01D4BC09562Q34008552-1A508939-3EE5-4E50-8439-346ED112760BQ34012873-471CE873-16A9-4AF9-92FD-3D06392B42DAQ34085058-4CE1A561-7D1C-41ED-B23D-1FF761C357A7Q34090872-8F0681F9-3CF2-4FF3-8C79-B625121711D2Q34102001-4A18DC3B-6129-479F-B6E8-381DDBEF3C2AQ34163582-E446A930-EA5C-4C78-87C4-A8929930919CQ34165921-D40FFE34-07D8-477C-8398-5DBC9EED220CQ34225745-6B7257C8-BB59-4647-93DB-C7A82A8AB580Q34382307-2906D054-2CF1-491D-BA3F-0B99957F4EDCQ34382683-C0346348-1F05-4707-AECB-4414CDCB1F4AQ34391646-91C25EF9-8E58-4156-B85A-3B851D98A0C5Q34400980-68F4B12C-4A7C-42E1-A113-C4C1C39242EEQ34435128-7AB077EF-237E-490F-A365-C75AB5786097
P2860
Nonalcoholic steatohepatitis: an expanded clinical entity.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Nonalcoholic steatohepatitis: an expanded clinical entity.
@en
Nonalcoholic steatohepatitis: an expanded clinical entity.
@nl
type
label
Nonalcoholic steatohepatitis: an expanded clinical entity.
@en
Nonalcoholic steatohepatitis: an expanded clinical entity.
@nl
prefLabel
Nonalcoholic steatohepatitis: an expanded clinical entity.
@en
Nonalcoholic steatohepatitis: an expanded clinical entity.
@nl
P2093
P1433
P1476
Nonalcoholic steatohepatitis: an expanded clinical entity
@en
P2093
B A Neuschwander-Tetri
C G Janney
M J Farahvash
P304
P356
10.1016/0016-5085(94)90235-6
P407
P577
1994-10-01T00:00:00Z